ClinicalTrials.gg
CompletedNCT04116476Updated May 15, 2023

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

A Phase 1 interventional study of MT-7117 in Mild and Moderate Hepatic Impairment, sponsored by Mitsubishi Tanabe Pharma America Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Mitsubishi Tanabe Pharma America Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2021, 5 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,187 studies in Lymphoma, Follicular with a site in United States — 129 open to participants now, 218 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Enrollment
708th of 1,017
23 · median 38
Started
2019
with 31 others
Phase 1
365 of 1,187
37 open now
Registered
929th of 1,187
by date

Among the 1,187 studies in Lymphoma, Follicular with a site in United States, this one is the 708th largest by enrollment of the 1,017 interventional ones that give a count, is one of 32 that started in 2019, is one of 365 in phase 1, and was the 929th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

129 of the 1,187 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

124 more — sign in →

All 129 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function

03

Conditions studied

  • Mild and Moderate Hepatic Impairment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects 18 to 75 years of age inclusive
  • 18 -35 kg/m2
  • If female, you are nonpregnant, non-lactating and willing to utilize approved methods of .

Exclusion criteria

Exclusion Criteria:

  • Subjects who have mild or moderate hepatic impairment according to classification system at Screening (except normal healthy matches)
  • Subjects who have a known (CS) to MT-7117 or related compounds, including melatonin.
  • Subjects who have previously participated in a study involving MT-7117 or taken any other drug within 30 days or 5 half-lives prior to the first dose of IMP, whichever is longer.
  • Subjects who have a CS or unstable neurological, renal, cardiovascular, gastrointestinal, pulmonary, or hematologic disease for 14 days prior to enrollment.
  • Subjects who have used any prescription or over-the-counter (OTC) medication within 14 days prior to first dose of IMP, except for occasional use of acetaminophen (\< 1 g/day for normal hepatic subjects, and \< 2 g/day for hepatically impaired subjects) or any other medication approved by the sponsor (a case-by-case basis). For hepatic impaired subjects, prescribed medication or OTC may be permitted by the Investigator and sponsor on a case-by-case basis.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Impairment

    Drug: MT-7117

  • Experimental
    Normal Healthy Matches

    Drug: MT-7117

  • Experimental
    Mild Hepatic Impairment

    Drug: MT-7117

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of MT-7117

    Time frame: 0-96 Hours

  2. Area under the plasma concentration time curve from time zero to the time of last quantifiable concentration (AUC0-last) of MT-7117

    Time frame: 0-96 Hours

  3. Area under the plasma concentration time curve from time zero to infinity (AUC0-∞) of MT-7117

    Time frame: 0-96 Hours

Secondary outcomes

  1. Time to reach maximum plasma concentration (tmax) of MT-7117

    Time frame: 0-96 Hours

  2. Plasma terminal elimination half-life (t1/2) of MT-7117

    Time frame: 0-96 Hours

  3. Apparent oral clearance (CL/F) of MT-7117

    Time frame: 0-96 Hours

  4. Apparent volume of distribution (Vz/F) of MT-7117

    Time frame: 0-96 Hours

  5. fraction of unbound drug in plasma or serum (fu) of MT-7117

    Time frame: 0-96 Hours

  6. Number of participants with Adverse events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 0-96 Hours

07

Study locations

1 site
  • University of Miami Clinical Pharmacology Unit
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Feb 2021, 18 months.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 71. This study's 18 months is below that.

Counting every sponsor, half of 173 studies reached it within 51 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2019
First posted
Oct 4, 2019
StartActual
Aug 1, 2019
Primary completionActual
Feb 16, 2021
CompletionActual
Feb 16, 2021
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04116476
Responsible party
Sponsor
First posted
Oct 4, 2019
Start date
Aug 1, 2019
Primary completion
Feb 16, 2021
Completion
Feb 16, 2021
Last update
May 15, 2023

Study contacts

Head of Medical Science
study director · Mitsubishi Tanabe Pharma America Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion